Department of Internal Medicine, Hôpital neuchâtelois, Rue de la Maladière 45, 2000, Neuchâtel, Switzerland.
Department of Internal Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland.
Clin Rheumatol. 2020 Jan;39(1):5-8. doi: 10.1007/s10067-019-04714-y. Epub 2019 Aug 2.
Lower urinary tract symptoms (LUTS) have long been overlooked in systemic sclerosis (SSc). However, they are out of proportion of what would be expected based on age, sex, and presence of usual risk factors. Thus, there must be specific scleroderma-related mechanisms to result in LUTS. Fibrosis, nervous involvement (notably, dysautonomia), early signs of menopauses, and functional restriction play certainly a role, but available evidence shows inconsistent results. Thus, these factors are not sufficient to explain all aspect of LUTS in SSc. In vitro experiments point out a promising alternative mechanism, already observed in other rheumatologic diseases: an antibody-mediated etiology. However, more research is needed to better understand the pathophysiology of LUTS in SSc and develop specific treatment.
下尿路症状(LUTS)在系统性硬化症(SSc)中长期被忽视。然而,它们与年龄、性别和常见危险因素所预期的不成比例。因此,必然存在导致 LUTS 的特定的与硬皮病相关的机制。纤维化、神经受累(特别是自主神经功能紊乱)、绝经前期的早期迹象以及功能受限肯定起作用,但现有证据显示结果不一致。因此,这些因素不足以解释 SSc 中 LUTS 的所有方面。体外实验指出了一种有前途的替代机制,已经在其他风湿性疾病中观察到:抗体介导的病因。然而,需要进一步的研究来更好地理解 SSc 中 LUTS 的病理生理学,并开发出特定的治疗方法。